Data Sheet (Cat.No.T14894)

TargetMol

CC-90003

Chemical Properties



CAS No. : 1621999-82-3

Formula: C22H21F3N6O2

Molecular Weight: 458.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	CC-90003 is a selective inhibitor of ERK 1/2. It has antitumor activity.
Targets(IC50)	ERK
In vitro	CC-90003 is an irreversible and selective ERK 1/2 inhibitor with antitumor activity [1].

Solubility Information

Solubility	DMSO: 125 mg/mL (272.66 mM),Sonication is recommended. H2O: < 0.1 mg/mL (insoluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.73 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1813 mL	10.9066 mL	21.8131 mL
5 mM	0.4363 mL	2.1813 mL	4.3626 mL
10 mM	0.2181 mL	1.0907 mL	2.1813 mL
50 mM	0.0436 mL	0.2181 mL	0.4363 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Monica M. Mita, et al. A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors. Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2577-2577.

Jin X, Yang Y, Liu D, et al.Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation.Cell Communication and Signaling.2024, 22(1): 565.